tbuckley/cabot-search huggingface dataset:
Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: The SIRveNIB study.
Authors: Pierce H. W. Chow, Mihir Gandhi
Journal: Journal of Clinical Oncology (2017)

4002 Background: The optimal therapeutic regime for locally advanced hepatocellular carcinoma (HCC) with and without vascular invasion remains unclear. This study evaluates the efficacy of Selective Internal Radiation Therapy using SIR-Spheres yttrium-90 microspheres (Y90) versus sorafenib in Asian Barcelona Clinic Liver Cancer (BCLC) stage B and C patients without extra-hepatic metastasis. Methods: This investigator-initiated multi-center trial randomized eligible patients with locally advanced inoperable HCC to single injection of Y90 or sorafenib (oral 400mg BD) till progressive disease or unacceptable toxicity. The sample size, assuming type I error (two-sided) of 0.05 and power of 90% was 360 patients. Final analysis was planned at 266 reported deaths. Results: 360 patients (182 Y90, 178 sorafenib) were enrolled from 27 centers in 11 Asian countries. BCLC C patients without extra-hepatic metastasis comprised 41.4% of patients, 30.6% had portal vein thrombosis (PVT), 88.6% were Child-Pugh A, 57.2% were hepatitis B and 15.0% were hepatitis C. Altogether 28.6% and 9.0% of patients in the Y90 and sorafenib arms respectively failed to receive planned therapy. Intention-to-treat analysis was carried out with the overall survival (OS) in the Y90 and sorafenib arms being 8.54 and 10.58 months respectively (Hazard ratio (HR) 1.17, p =0.203). Tumour response rate (TRR) was 16.5% and 1.7% (p &lt; 0.001) respectively. Time-to-tumor -progression (TTP) was 5.88 vs 5.36 (overall) (HR 0.93) and 6.08 vs 5.39 (liver-specific) (HR 0.91) months for Y90 and sorafenib respectively. Progression-free-survival (PFS) was 5.29 vs 5.06 (overall) (HR 0.94) and 5.85 vs 5.06 (liver-specific) (HR 0.92) months respectively. At least one severe adverse event was found in 27.7% and 50.6% of patients in the Y90 and sorafenib arms respectively. Conclusions: Asian patients with locally advanced HCC without extra-hepatic metastasis treated with Y90 have statistically significant better TRR, and fewer SAEs when compared with those treated with sorafenib. There were no statistically significant differences in OS between Y90 and sorafenib. Clinical trial information: NCT01135056.
Drug Treatment for Early-Stage COPD
Authors: Fanny W.S. Ko, Gary W.K. Wong
Journal: New England Journal of Medicine (2017)

Chronic obstructive pulmonary disease (COPD) is a common disease with an estimated global prevalence of 11.7%, affecting almost 400 million people around the world.1 In the United States, approximately 14% of adults 40 to 79 years of age have COPD.2 Although the prevalence of different stages of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)3 varies among different countries,4 early-stage COPD — stage 1 disease, a facet of which is a forced expiratory volume in 1 second (FEV1) of 80% or more of the predicted value, and stage 2 disease, which includes an FEV1 of . . .
マルチモーダル腫瘍診断と治療のためのCu(II)をドープしたポリアニリンナノシャトル【Powered by NICT】
Authors: Lin Min, Wang Dandan, Li Shuyao, Tang Qi, Liu Shuwei, Ge Rui, Liu Yi, Zhang Daqi, Sun Hongchen, Zhang Hao, Yang Bai
Journal: Biomaterials (2016)
Diagnosis and management of endometriosis: summary of NICE guidance
Authors: Laura Kuznetsov, Katharina Dworzynski, Melanie Davies, Caroline Overton
Journal: BMJ (2017)

#### What you need to know

Endometriosis is one of the most common gynaecological disorders, affecting an estimated 10% of women in the reproductive age group (usually 15-49 years old), and in the UK it is the second most common gynaecological condition (after fibroids).1 Endometriosis is hormone mediated and is associated with menstruation. The precise cause is not known, but it is widely accepted that endometrial cells deposited in the pelvis by retrograde menstruation are capable of implantation and development. It is a long term condition causing pelvic pain, painful periods, and subfertility. Endometriosis presents a diagnostic and clinical challenge, with many women left undiagnosed, often for many years. Small observational studies have reported delays of 4-10 years in diagnosis,2 3 which can result in decreased quality of life4 and disease progression.5 The diagnostic delay is not limited to adults; endometriosis is also often missed in adolescent girls,6 and this guideline aims to improve care by highlighting this age group in some recommendations.

This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE) on diagnosis and management of endometriosis.7 The recommendations were based on …
Ventricular Fibrillation in the Wolff-Parkinson-White Syndrome
Authors: George J. Klein, Thomas M. Bashore, T. D. Sellers, Edward L. C. Pritchett, William M. Smith, John J. Gallagher
Journal: New England Journal of Medicine (1979)

To examine the risk of ventricular fibrillation in patients with the Wolff-Parkinson-White syndrome, we compared patients who had this syndrome and a history of ventricular fibrillation related to preexcitation with patients who had the syndrome without this history. Ventricular fibrillation occurred during atrial fibrillation, with rapid conduction over the accessory pathway, and these patients had a higher prevalence of both reciprocating tachycardia and atrial fibrillation (14 of 25 vs. 18 of 73, P = 0.004) and multiple accessory pathways (five of 25 vs. four of 73, P = 0.012). The shortest preexcitation R-R interval during atrial fibrillation was less in the group with ventricular fibrillation (mean shortest R-R, 180 vs. 240 milliseconds, P<0.0001) as was the average R-R interval (mean average R-R, 269 vs. 340 milliseconds, P<0.0001). Patients with Wolff-Parkinson-White syndrome who are most susceptible to ventricular fibrillation have a history of atrial fibrillation and reciprocating tachycardia, demonstrate rapid conduction over an accessory pathway during atrial fibrillation and have multiple accessory pathways. (N Engl J Med 301:1080–1085, 1979)
Benefits of Electronic Medical Record Banks
Authors: Richard F. Gibson
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Progress towards antimicrobial resistance containment and control in Indonesia
Authors: Harry Parathon, Kuntaman Kuntaman, Tri Hesty Widiastoety, Bayu T Muliawan, Anis Karuniawati, Mariyatul Qibtiyah, Zunilda Djanun, Jihane F Tawilah, Tjandra Aditama, Visanu Thamlikitkul, Sirenda Vong
Journal: BMJ (2017)

A pilot programme to evaluate Indonesia's antimicrobial resistance containment plan shows that progress is on the right track, but substantial strengthening is needed, say <b>Harry Parathon and colleagues</b>
The HGF/c-Met pathway activates COX-2 in non-small cell lung cancer
Authors: Jill M. Siegfried, Christopher T. Gubish, Pierre E. Queiroz de Oliveira, Laura P. Stabile
Journal: Cancer Research (2006)

173   Lung cancer is currently the leading cause of cancer mortality in U.S. men and women. Growth factors and their receptors play important roles in the growth and progression of lung tumors and are potential therapeutic targets for lung cancer treatment. Several studies have suggested a possible role of the hepatocyte growth factor (HGF)/c-Met system in tumor development and progression. HGF and its receptor, c-Met, have both been shown to be negative prognostic indicators of survival and recurrence in non-small cell lung cancer (NSCLC). Some of the oncogenic actions of HGF are thought to be mediated by cyclooxygenase-2 (COX-2) resulting in the production of prostaglandin E2 (PGE2). We studied four NSCLC cell lines (201T, 273T, H23, 128-88T) each expressing different basal levels (relative range 0.23-1) of COX-2 protein for the effects of HGF on COX-2. Addition of 50ng/ml HGF increased COX-2 protein expression 10-fold by 2 hours following serum deprivation in NSCLC cells with low basal levels of COX-2 expression. The HGF induction of COX-2 occurred through both the Erk 1/2 and p38 pathways while the PI3 kinase pathway was not involved in this response. Increased COX-2 protein due to HGF stimulation in NSCLC cells resulted in a maximum 4-fold increase at 24 hours in PGE2 production and secretion demonstrated by ELISA. In turn, 100 μM PGE2 treatment of NSCLC cell lines increased cell proliferation 4-fold as measured by MTT assay. Addition of 100 μM PGE2 to normal lung fibroblasts increased production and secretion of HGF by 5-fold as measured by ELISA. These results suggest that a paracrine loop is involved in this response where stroma simulates epithelium and epithelium stimulates stroma. Additive anti-proliferative effects were observed when treating NSCLC cells  in vitro  with agents that target both the HGF/c-Met (c-Met antisense) and COX-2 pathways (celecoxib) versus either c-Met antisense or celecoxib alone. These preliminary findings warrant further studies into the mechanism of action of HGF on the COX-2 pathway and the effects of inhibiting this pathway as a potential therapeutic strategy for lung cancer. This work was supported by NIH grant CA79882.
Abstract 12156: Greater Regression of Coronary Atherosclerosis With the Pre-Beta High-Density Lipoprotein Mimetic CER-001 in Patients With More Extensive Plaque Burden
Authors: Yu Kataoka, Jordan Andrews, MyNgan Duong, Tracy Nguyen, Nisha Schwarz, Jessica Fendler, Rishi Puri, Julie Butters, Constance Keyserling, Jofn F Paolini, Jean-Louis Dasseux, Stephen J Nicholls
Journal: Circulation (2015)

Introduction: Infusing high-density lipoprotein (HDL) has been shown to promote plaque regression in patients with acute coronary syndrome (ACS). The factors associated with a greater propensity to regression have not been elucidated. We hypothesized greater plaque regression with HDL infusion would be observed in patients with greater baseline plaque burden. Methods: The CHI-SQUARE study compared the effect of infusing the pre-beta HDL mimetic CER-001 (3 to 12 mg/kg) versus placebo weekly for 5 weeks in patients with a recent ACS on plaque burden using serial intravascular ultrasound. Receiver operating characteristics curve analysis determined that a baseline percent atheroma volume (PAV) ≥30% optimally associated with greater regression. Clinical and imaging characteristics were compared in patients with baseline PAV &lt;30% (n=74) or ≥30% (n=271). Results: There were no differences between the groups apart from greater use of statin in patients with baseline PAV ≥30% (100 v. 90%, p=0.01). Patients with a greater baseline PAV were more likely to demonstrate echolucency (20 v. 9%, p=0.02) and ultrasound attenuation (21 v. 7%, p=0.01), consistent with lipidic and inflammatory material. On serial evaluation, PAV decreased with CER-001 infusion in patients with baseline PAV ≥30% by -0.27% (p=0.01 v. baseline), but not in those with baseline PAV &lt;30% (+0.43%, p=0.15 v. baseline, p=0.01 between plaque burden groups). The greatest PAV regression was observed with infusing CER-001 3 mg/kg in patients with baseline PAV ≥30% by 0.96% (p=0.04 v. baseline, p=0.02 v. placebo) (Table), but not in those patients with baseline PAV &lt;30% (+0.08%, p=0.55 v. baseline, p=0.004 for comparison between plaque burden groups). Conclusions: Greater plaque regression with CER-001 3 mg/kg was observed in ACS patients with greater atheroma burden and more vulnerable features. The findings identify ACS patients with high-risk plaque features most likely to benefit from HDL mimetic therapy.
EPA Treatment Shortly after Primary PCI in Patients with Acute Coronary Syndromes: One Year Outcomes of a Randomized, Controlled Study
Authors: Nosaka Kazumasa, Doi Masayuki, Miyoshi Toru, Matsuo Naoaki, Nishibe Tomoyuki, Sogo Masahiro, Tsukuda Saori, Okada Tomoaki, Ohkawa Keisuke, Sakane Kosuke, Takeda Ko, Itoh Hiroshi
Journal: Circulation (2016)
THU0433 Pharmacodynamic and pharmacokinetic study of verinurad (RDEA3170) in adult male subjects with mild, moderate, and severe renal impairment: a phase 1, open-label study
Authors: WB Smith, J Hall, JK Berg, M Kazimir, A Yamamoto, S Walker, C Lee, TC Marbury
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. <h3>Objectives</h3> This Phase 1, single-dose, open-label study investigated the pharmacodynamics (PD), pharmacokinetics (PK), and safety of oral verinurad in adult subjects with mild, moderate, or severe renal impairment and matched controls with normal renal function (NCT02219516). <h3>Methods</h3> Adult males aged 18–85 years were enrolled with a screening serum uric acid (sUA) 4.5–10 mg/dL and creatinine clearance calculated by Cockcroft-Gault formula of 60 to &lt;90 mL/min (mild renal impairment), 30 to &lt;60 mL/min (moderate impairment), 15 to &lt;30 mL/min (severe impairment), or ≥90 mL/min (matched controls). Oral verinurad 15 mg was administered once under fasted conditions. Serial blood and urine samples were taken 30 min before and up to 72 hours postdose. Safety assessments included laboratory, ECG, and vital sign parameters as well as adverse event (AEs) reporting. <h3>Results</h3> PD data were based on 7–8 subjects per group. Verinurad decreased sUA in all groups, with greatest changes in the normal function and mild renal impairment groups. Mean (SD) maximal % change in sUA from baseline (Emax) was -38.3 (14.8)%, -36.9 (13.6)%, -20.5 (6.64)%, and -12.6 (6.94)%, respectively, in the normal function and mild, moderate, and severe renal impairment groups. Increase in the amount of excretion of uric acid due to verinurad treatment decreased in subjects with moderate and severe renal impairment. Plasma Cmax and AUC of verinurad increased with decreasing renal function. Verinurad at the 15 mg dose was well tolerated, with no serious AEs, no subject withdrawals due to AEs, and no Renal Events Adjudication Committee (REAC)-adjudicated renal events during treatment. One patient in each renal impairment group had treatment-emergent AEs considered possibly related to verinurad, which were categorized as gastrointestinal in nature. There were no clinically meaningful changes noted in laboratory values or vital signs. <h3>Conclusions</h3> The sUA lowering effect of verinurad was observed across the spectrum of renal function. Consistent with the verinurad renal-dependent mechanism of action, decreasing sUA lowering was demonstrated with increasing renal impairment. Verinurad safety and tolerability were similar across all stages of renal impairment. <h3>Disclosure of Interest</h3> W. Smith Employee of: Volunteer Research Goup, J. Hall Employee of: Ardea Biosciences, Inc., J. Berg Employee of: DaVita Clinical Research, M. Kazimir Employee of: DaVita Clinical Research, A. Yamamoto Employee of: Ardea Biosciences, Inc., S. Walker Employee of: AstraZeneca, C. Lee Employee of: Ardea Biosciences, Inc., T. Marbury Employee of: Orlando Clinical Research Center
Toward Consistent Methodology to Quantify Populations in Proximity to Oil and Gas Development: A National Spatial Analysis and Review
Authors: Eliza D. Czolowski, Renee L. Santoro, Tanja Srebotnjak, Seth B.C. Shonkoff
Journal: Environmental Health Perspectives (2017)

Background: Higher risk of exposure to environmental health hazards near oil and gas wells has spurred interest in quantifying populations that live in proximity to oil and gas development. The available studies on this topic lack consistent methodology and ignore aspects of oil and gas development of value to public health–relevant assessment and decision-making. Objectives: We aim to present a methodological framework for oil and gas development proximity studies grounded in an understanding of hydrocarbon geology and development techniques. Methods: We geospatially overlay locations of active oil and gas wells in the conterminous United States and Census data to estimate the population living in proximity to hydrocarbon development at the national and state levels. We compare our methods and findings with existing proximity studies. Results: Nationally, we estimate that 17.6 million people live within 1,600m (∼1 mi) of at least one active oil and/or gas well. Three of the eight studies overestimate populations at risk from actively producing oil and gas wells by including wells without evidence of production or drilling completion and/or using inappropriate population allocation methods. The remaining five studies, by omitting conventional wells in regions dominated by historical conventional development, significantly underestimate populations at risk. Conclusions: The well inventory guidelines we present provide an improved methodology for hydrocarbon proximity studies by acknowledging the importance of both conventional and unconventional well counts as well as the relative exposure risks associated with different primary production categories (e.g., oil, wet gas, dry gas) and developmental stages of wells. https://doi.org/10.1289/EHP1535
Histamine and Toll-like receptor ligands synergistically induce endothelial cell gap formation by the extrinsic coagulating pathway
Authors: Yuhki Yanase, Satoshi Morioke, Kazumasa Iwamoto, Shunsuke Takahagi, Kazue Uchida, Tomoko Kawaguchi, Kaori Ishii, Izumi Hide, Michihiro Hide
Journal: Journal of Allergy and Clinical Immunology (2017)
A Tale of Two Epidemics — HCV Treatment among Native Americans and Veterans
Authors: Brigg Reilley, Jessica Leston
Journal: New England Journal of Medicine (2017)

Interview with Brigg Reilley on why the Indian Health Service has lagged when it comes to treating patients with hepatitis C. (06:09)Download In recent years, the Department of Veterans Affairs health care system has mounted a response to hepatitis C that should be the envy of any health system. On the other hand, the Indian Health Service is struggling to meet the needs of its patients with hepatitis C.
A functional genomics predictive network model identifies regulators of inflammatory bowel disease
Authors: Lauren A Peters, Jacqueline Perrigoue, Arthur Mortha, Alina Iuga, Won-min Song, Eric M Neiman, Sean R Llewellyn, Antonio Di Narzo, Brian A Kidd, Shannon E Telesco, Yongzhong Zhao, Aleksandar Stojmirovic, Jocelyn Sendecki, Khader Shameer, Riccardo Miotto, Bojan Losic, Hardik Shah, Eunjee Lee, Minghui Wang, Jeremiah J Faith, Andrew Kasarskis, Carrie Brodmerkel, Mark Curran, Anuk Das, Joshua R Friedman, Yoshinori Fukui, Mary Beth Humphrey, Brian M Iritani, Nicholas Sibinga, Teresa K Tarrant, Carmen Argmann, Ke Hao, Panos Roussos, Jun Zhu, Bin Zhang, Radu Dobrin, Lloyd F Mayer, Eric E Schadt
Journal: Nature Genetics (2017)
Morphology and Growth of Subcutaneous Tumors Induced with Carcinogenic Hydrocarbons in Strain C3H Male Mice
Authors: Michael B. Shimkin, W. Ray Bryan
Journal: JNCI Journal of the National Cancer Institute (1943)

Morphology and Growth of Subcutaneous Tumors Induced with Carcinogenic Hydrocarbons in Strain C3H Male Mice Get access Michael B. Shimkin, Michael B. Shimkin past assistant surgeon Search for other works by this author on: Oxford Academic PubMed Google Scholar W. Ray Bryan W. Ray Bryan biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 1, August 1943, Pages 25–35, https://doi.org/10.1093/jnci/4.1.25 Published: 01 August 1943
Antigenicity of Pooled Human Malignant and Normal Tissues by Cytoimmunological Technique. III. Distribution of Tumor Antigen&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1961)

Horse antiserum to pooled human carcinoma preparations displayed toxicity for monolayer cultures of HeLa cells. This toxicity was no longer present after absorption of the serum by human carcinomas. Each of 60 individually tested carcinomas absorbed approximately the same amount of toxic material. The relative amount of absorbing antigen in these tumors showed a standard deviation of ± 30 percent. Preparations from established cell strains, HeLa (Gey), Detroit-6 (Berman and Stulberg), conjunctiva (Chang), and heart (Girardi), also were able to remove the toxicity from the antiserum. Thus, 60 human carcinomas and atypical cells of established tissue-culture lines possessed a common antigen which was pertinent for the initiation of cytotoxic manifestations with the exposure in vitro of atypical cells to the horse antiserum. This antigen presumably constitutes a part of the plasma membrane.
ステント血栓症,左室内血栓,下肢動脈血栓症をきたしたヘパリン起因性血小板減少症患者の1例
Authors: 西山裕善, 柳志郎, 岩田真一, 石下晃子, 紙森公雄, 太田剛弘
Journal: Circulation (2008)
Reducing the Global Burden of Cardiovascular Disease, Part 2
Authors: Darryl P. Leong, Philip G. Joseph, Martin McKee, Sonia S. Anand, Koon K. Teo, Jon-David Schwalm, Salim Yusuf
Journal: Circulation Research (2017)

In this second part of a 2-part series on the global burden of cardiovascular disease, we review the proven, effective approaches to the prevention and treatment of cardiovascular disease. We specifically review the management of acute cardiovascular diseases, including acute coronary syndromes and stroke; the care of cardiovascular disease in the ambulatory setting, including medical strategies for vascular disease, atrial fibrillation, and heart failure; surgical strategies for arterial revascularization, rheumatic and other valvular heart disease, and symptomatic bradyarrhythmia; and approaches to the prevention of cardiovascular disease, including lifestyle factors, blood pressure control, cholesterol-lowering, antithrombotic therapy, and fixed-dose combination therapy. We also discuss cardiovascular disease prevention in diabetes mellitus; digital health interventions; the importance of socioeconomic status and universal health coverage. We review building capacity for conduction cardiovascular intervention through strengthening healthcare systems, priority setting, and the role of cost effectiveness.